TIP832: Fairfax Financial (FFO.TO): The Berkshire Of The North w/ Kyle Grieve & Shawn O'Malley
Episode
66 min
Read time
3 min
Topics
Career Growth, Investing, Fundraising & VC
AI-Generated Summary
Key Takeaways
- ✓Float as free leverage: Fairfax grew its insurance float from $13M in 1985 to $40.8B today by acquiring underperforming insurers and deploying float capital at 7.7% long-term returns versus the industry average of ~4%. When combined with a sub-100% combined ratio (averaging ~97% since 2006), the company effectively gets paid to hold and invest other people's money — a structural advantage most insurers never achieve simultaneously.
- ✓Post-GFC hedging mistake: Fairfax netted $4.6B from CDS bets during the 2008 crisis — four times Michael Burry's gain — but then spent 2010–2016 shorting the S&P 500 and Russell 2000, wiping out nearly all operating income and limiting book value growth to 2% annually. Watsa publicly admitted the error and permanently abandoned shorting. Investors should recognize that crisis-era scars systematically distort future risk assessments, even for elite capital allocators.
- ✓Tactical buyback execution: During COVID-19, Fairfax purchased total return swaps on its own stock after shares dropped ~50%, ultimately generating ~$2B in cash proceeds used for further share repurchases. Share count declined from 28M to 23M since 2018, with buybacks executed at prices as low as $473–$500 versus today's ~$2,340. Timing buybacks at maximum pessimism, not all-time highs, is the key differentiator between value-destructive and value-creative capital return programs.
- ✓Non-dilutive options structure: Fairfax grants equity awards using shares already purchased on the open market rather than newly issued shares, making compensation entirely non-dilutive — a structure described as exceptionally rare. Vesting runs 50% at five years and 50% at ten years, with expiration dates extending past 2040. This forces boards to treat compensation as a real cash expense, naturally constraining package sizes and aligning executive time horizons with long-term shareholder value creation.
- ✓Insurance valuation framework: Evaluate insurance holding companies using return on equity rather than ROIC, then apply a price-to-book multiple to terminal book value. At Fairfax's stated 15% ROE target (below its five-year average of ~21%), applying a 1.3x book multiple produces a 2030 terminal value of ~CAD $4,600 including dividends, implying ~14.7% annualized returns. Bear case at 11% ROE with 1.0x book still yields ~5.3% annually, demonstrating meaningful downside protection.
What It Covers
Kyle Grieve and Shawn O'Malley analyze Fairfax Financial (FFH.TO), a Canadian insurance holding company led by Prem Watsa that has compounded book value at 18% annually since 1985. The episode covers Fairfax's business model, GFC bet, capital allocation strategies, competitive advantages, management structure, valuation, and comparison to Berkshire Hathaway.
Key Questions Answered
- •Float as free leverage: Fairfax grew its insurance float from $13M in 1985 to $40.8B today by acquiring underperforming insurers and deploying float capital at 7.7% long-term returns versus the industry average of ~4%. When combined with a sub-100% combined ratio (averaging ~97% since 2006), the company effectively gets paid to hold and invest other people's money — a structural advantage most insurers never achieve simultaneously.
- •Post-GFC hedging mistake: Fairfax netted $4.6B from CDS bets during the 2008 crisis — four times Michael Burry's gain — but then spent 2010–2016 shorting the S&P 500 and Russell 2000, wiping out nearly all operating income and limiting book value growth to 2% annually. Watsa publicly admitted the error and permanently abandoned shorting. Investors should recognize that crisis-era scars systematically distort future risk assessments, even for elite capital allocators.
- •Tactical buyback execution: During COVID-19, Fairfax purchased total return swaps on its own stock after shares dropped ~50%, ultimately generating ~$2B in cash proceeds used for further share repurchases. Share count declined from 28M to 23M since 2018, with buybacks executed at prices as low as $473–$500 versus today's ~$2,340. Timing buybacks at maximum pessimism, not all-time highs, is the key differentiator between value-destructive and value-creative capital return programs.
- •Non-dilutive options structure: Fairfax grants equity awards using shares already purchased on the open market rather than newly issued shares, making compensation entirely non-dilutive — a structure described as exceptionally rare. Vesting runs 50% at five years and 50% at ten years, with expiration dates extending past 2040. This forces boards to treat compensation as a real cash expense, naturally constraining package sizes and aligning executive time horizons with long-term shareholder value creation.
- •Insurance valuation framework: Evaluate insurance holding companies using return on equity rather than ROIC, then apply a price-to-book multiple to terminal book value. At Fairfax's stated 15% ROE target (below its five-year average of ~21%), applying a 1.3x book multiple produces a 2030 terminal value of ~CAD $4,600 including dividends, implying ~14.7% annualized returns. Bear case at 11% ROE with 1.0x book still yields ~5.3% annually, demonstrating meaningful downside protection.
- •Decentralization as retention tool: Fairfax maintains presidents at subsidiary insurance companies for multiple decades by acquiring well-run businesses and leaving management structures intact. Internal promotion is the default, not the exception. This matters in insurance specifically because underwriting quality only reveals itself across multiple cycles — firing managers mid-cycle before reserve deficiencies or redundancies surface destroys institutional knowledge and resets the underwriting improvement timeline by years.
Notable Moment
Fairfax sold a 10% stake in its Odyssey reinsurance subsidiary at 1.7x book value — a premium multiple — then used those proceeds to repurchase Fairfax shares trading at just 0.9x book. The maneuver simultaneously monetized an overvalued asset and bought an undervalued one, concentrating shareholder ownership without issuing new capital.
You just read a 3-minute summary of a 63-minute episode.
Get We Study Billionaires summarized like this every Monday — plus up to 2 more podcasts, free.
Pick Your Podcasts — FreeKeep Reading
More from We Study Billionaires
TIP831: Pinduoduo (PDD): Is PDD the Best Buy in China? w/ Daniel Mahncke and Shawn O'Malley
Jul 16 · 87 min
This Week in Startups
Why SpaceX Buying Cursor Changes Everything
Jun 18
More from We Study Billionaires
TIP830: SpaceX (SPCX): Is It Really Worth $2 Trillion Dollars? w/ Kyle Grieve & Shawn O'Malley
Jul 12 · 73 min
The Daily (NYT)
A Gen Z Revolution at the Movies
Jun 16
More from We Study Billionaires
We summarize every new episode. Want them in your inbox?
TIP831: Pinduoduo (PDD): Is PDD the Best Buy in China? w/ Daniel Mahncke and Shawn O'Malley
TIP830: SpaceX (SPCX): Is It Really Worth $2 Trillion Dollars? w/ Kyle Grieve & Shawn O'Malley
TIP829: Kaspi Stock ($KSPI): The Cheapest E-Commerce Monopoly in the World w/ Daniel Mahncke and Shawn O'Malley
TIP828: Restoration Hardware (RH): Building a Luxury Empire From Scratch w/ Shawn O'Malley and Daniel Mahncke
TIP827: Auto1 Stock (AG1): Is This the Amazon for Cars? w/ Daniel Mahncke & Shawn O’Malley
Similar Episodes
Related episodes from other podcasts
This Week in Startups
Jun 18
Why SpaceX Buying Cursor Changes Everything
The Daily (NYT)
Jun 16
A Gen Z Revolution at the Movies
The Knowledge Project
Jun 9
Mental Models That Change How You Think | Bill Gurley
Investing for Beginners
May 21
Birdseye View: Caterpillar (CAT) — Moat, Dealers, and the “Picks & Shovels” of the AI Boom
Odd Lots
Apr 16
Brad Setser on the War in Iran and the Future of the US Dollar
Explore Related Topics
This podcast is featured in Best Investing Podcasts (2026) — ranked and reviewed with AI summaries.
Read this week's Investing & Markets Podcast Insights — cross-podcast analysis updated weekly.
You're clearly into We Study Billionaires.
Every Monday, we deliver AI summaries of the latest episodes from We Study Billionaires and 192+ other podcasts. Free for one show.
Start My Monday DigestNo credit card · Unsubscribe anytime